Trabectedin plus radiation for select soft tissue sarcomas
Treatments studied
Part of Cancer clinical trials.
This trial studies whether adding a chemotherapy medicine called trabectedin to targeted radiation can help control certain soft tissue sarcomas. It focuses on specific cancer types and locations, aiming to shrink tumors while keeping radiation safe for nearby healthy organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be able to sign informed consent before any study-only tests.
- Your sarcoma type and location must match the trial’s specific cohorts (lung-metastatic, myxoid liposarcoma, or retroperitoneal).
- Your cancer must be staged and confirmed with central review before enrollment.
- You must have measurable tumor disease and an ability to tolerate treatment (ECOG 0–1 or ≤1 depending on cohort).
- You must have adequate organ function for chemotherapy and radiation (blood counts, kidney/liver tests, and heart function).
- You must have a central venous catheter, and you must not have had prior trabectedin or prior radiation where not allowed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether giving radiation before surgery, along with anlotinib and penpulimab, can improve treatment for localized soft tissue sarcoma. It may help shrink or control the tumor before conservative surgery.
This trial studies a high-dose, shortened course of proton beam radiation for people with soft tissue sarcoma that cannot be removed by surgery. It aims to improve tumor control while reducing side effects.
This trial tests a shorter, 3-week course of radiation therapy (using protons or standard X-rays) given before surgery for localized soft tissue sarcoma. It aims to see if this approach is safe and effective for treating the tumor while reducing side effects.
This Phase 3 trial tests trabectedin (in tTF-NGR study) for people with advanced or metastatic soft-tissue sarcoma whose first treatment with anthracycline drugs didn’t work (or can’t be used). It aims to see if this approach works better than the study comparison treatment, using tumor response and other safety outcomes.
This trial tests whether adding immunotherapy drugs (anlotinib and penpulimab) to radiation before surgery can help treat soft tissue sarcoma—a type of cancer in muscles, fat, or connective tissue. The goal is to shrink the tumor and improve surgical outcomes.
This Phase 1/2 trial tests whether combining radiation with two targeted/immune medicines can shrink or control high-risk soft tissue sarcoma and improve outcomes. It may help patients whose tumors are large, hard to fully remove, or have come back after prior treatment.
Hear when a new Leiomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.